Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.
Department of Pathology, Nanjing Medical University, Nanjing, 211166, China.
BMC Gastroenterol. 2021 Jan 6;21(1):7. doi: 10.1186/s12876-020-01588-2.
Desmoglein2 (DSG2) is a transmembrane protein that helps regulate intercellular connections and contributes to desmosome assembly. Desmosome are associated with cell adhesion junctions, which play an important role in cancer progression specially cancer cell migration and invasion. However, DSG2 expression in colon cancer (CC) and its association with CC patients' overall survival (OS) are still unclear.
We collected 587 CC samples, 41 colitis tissues and 114 pericarcinomatous tissues, as well as corresponding clinicopathological data about the patients who contributed them. All samples were tested immunohistochemically in tissue microarrays. Kaplan-Meier method was used for calculating patient survival. Univariate and multivariate analyses was used for investigating DGS2 link with CC patient's clinicopathological factors. Bioinformatics analysis was also used in study.
The results showed that DSG2 expression was lower in CC tissues than in pericarcinomatous tissues (P < 0.001). DSG2 expression was associated with differentiation (P = 0.033), lymph node metastasis (P = 0.045), distant metastasis (P = 0.006) and AJCC stage (P < 0.001). Univariate analysis indicated that poor OS in patients with CC was associated with low DSG2 expression (P < 0.001), tumor size (P < 0.001), lymph node metastasis (P < 0.001), distant metastasis (P < 0.001), AJCC stage (P < 0.001) and venous invasion (P < 0.001). In multivariate analysis, low DSG2 expression (P < 0.001), distant metastasis (P < 0.001), AJCC stage (P = 0.002), venous invasion (P < 0.001) were independent prognostic factors for CC patients. Bioinformatics analysis indicated that low DSG2 expression affects protein activation, regulates the P53-related pathway in CC, and activates the EGFR pathway.
The results suggest that low DSG2 expression is associated with poor survival for CC patients. DSG2 could be a prognostic biomarker for CC.
桥粒芯糖蛋白 2（DSG2）是一种跨膜蛋白，有助于调节细胞间连接，并有助于桥粒组装。桥粒与细胞黏附连接有关，在癌症进展中起着重要作用，特别是在癌细胞迁移和侵袭中。然而，DSG2 在结肠癌（CC）中的表达及其与 CC 患者总生存期（OS）的关系尚不清楚。
我们收集了 587 例 CC 样本、41 例结肠炎组织和 114 例癌旁组织，以及为这些样本提供患者的相应临床病理资料。所有样本均在组织微阵列中进行免疫组织化学检测。Kaplan-Meier 法用于计算患者生存。单变量和多变量分析用于研究 DGS2 与 CC 患者临床病理因素的关系。还进行了生物信息学分析。
结果显示，CC 组织中 DSG2 的表达低于癌旁组织（P<0.001）。DSG2 的表达与分化（P=0.033）、淋巴结转移（P=0.045）、远处转移（P=0.006）和 AJCC 分期（P<0.001）有关。单变量分析表明，CC 患者的不良 OS 与 DSG2 表达低下（P<0.001）、肿瘤大小（P<0.001）、淋巴结转移（P<0.001）、远处转移（P<0.001）、AJCC 分期（P<0.001）和静脉侵犯（P<0.001）有关。多变量分析表明，低 DSG2 表达（P<0.001）、远处转移（P<0.001）、AJCC 分期（P=0.002）、静脉侵犯（P<0.001）是 CC 患者的独立预后因素。生物信息学分析表明，低 DSG2 表达影响蛋白激活，调节 CC 中 P53 相关通路，并激活 EGFR 通路。
结果表明，DSG2 表达低下与 CC 患者的不良预后有关。DSG2 可能是 CC 的预后生物标志物。
